Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €173.25 EUR
Change Today -1.04 / -0.60%
Volume 575.0
UTH On Other Exchanges
Symbol
Exchange
Frankfurt
As of 12:57 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTH) Snapshot

Open
€173.82
Previous Close
€174.29
Day High
€174.72
Day Low
€172.42
52 Week High
04/13/15 - €178.72
52 Week Low
06/18/14 - €62.62
Market Cap
8.1B
Average Volume 10 Days
207.5
EPS TTM
--
Shares Outstanding
46.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNITED THERAPEUTICS CORP (UTH)

united therapeutics corp (UTH) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTH) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

740 Employees
Last Reported Date: 02/24/15
Founded in 1996

united therapeutics corp (UTH) Top Compensated Officers

Founder, Chairman and Co-Chief Executive Offi...
Total Annual Compensation: $992.7K
Co-Chief Executive Officer, President and Dir...
Total Annual Compensation: $808.1K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

united therapeutics corp (UTH) Key Developments

Food and Drug Administration Approves Unituxin for the Treatment of Pediatric High-Risk Neuroblastoma

United Therapeutics Corporation announced that the United States Food and Drug Administration (FDA) has approved Unituxin Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence in the United States of approximately 700 patients, of whom 50% are diagnosed as having high-risk disease. Unituxin is a chimeric biologic antibody that induces cell lysis of GD2-expressing cells through antibody-dependent cell-mediated cytoxicity (ADCC) and complement-dependent cytoxicity (CDC) and is part of an immunotherapeutic regimen to treat pediatric high-risk neuroblastoma. The approval was based on demonstration of improved event-free survival (EFS) and overall survival (OS) in a multicenter, open-label, randomized trial (ANBL0032) conducted by the Children's Oncology Group (COG). The trial randomized (1:1) 226 patients to either the Unituxin/13-cis-retinoic acid (RA) arm or the RA alone arm. Patients in each arm received six cycles of treatment. The Unituxin/RA arm consisted of Unituxin in combination with granulocyte macrophage-colony stimulating factor and RA (cycles 1, 3, and 5), Unituxin in combination with interleukin-2 and RA (cycles 2 and 4), and RA (cycle 6). Patients were 11 months to 15 years of age (median age 3.8 years).

United Therapeutics Corporation Announces Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

United Therapeutics Corporation announced consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, total revenue was $346,363,000 compared to $289,017,000 a year ago. Operating income was $178,576,000 compared to loss of $28,491,000 a year ago. Income before income taxes was $174,764,000 compared to loss of $31,630,000 a year ago. Net income was $115,935,000 or $2.17 per diluted share compared to loss of $30,314,000 or $0.60 per diluted share a year ago. Non-GAAP earnings were $171,709,000 or $3.21 per diluted share compared to $160,203,000 or $2.88 per diluted share a year ago. Revenues for the quarter ended December 31, 2014 increased by $57.3 million, compared to the quarter ended December 31, 2013. The growth in revenues corresponded to the continued increase in the number of patients being treated with cardiopulmonary products and the commencement of Orenitram sales in 2014. For the year, total revenue was $1,288,519,000 compared to $1,116,984,000 a year ago. Operating income was $538,800,000 compared to $292,499,000 a year ago. Income before income taxes was $525,180,000 compared to $278,903,000 a year ago. Net income was $340,074,000 or $6.28 per diluted share compared to $174,560,000 or $3.28 per diluted share a year ago. Non-GAAP earnings were $590,956,000 or $10.91 per diluted share compared to $544,663,000 or $10.23 per diluted share a year ago.

United Therapeutics Corporation to Report Q4, 2014 Results on Feb 24, 2015

United Therapeutics Corporation announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Feb 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €173.25 EUR -1.04

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.126.90 CHF +2.90
Alexion Pharmaceuticals Inc $180.08 USD -4.50
Celanese Corp $65.85 USD +0.75
Nippon Shinyaku Co Ltd ¥4,175 JPY +60.00
Vertex Pharmaceuticals Inc $133.20 USD -2.62
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 29.7x
Price/Sales 6.9x
Price/Book 7.1x
Price/Cash Flow 25.6x
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.